Research programme: Islet Neogenesis Therapy for transplantation - Transition TherapeuticsAlternative Names: I.N.T.(TM) for transplantation; I.N.T.(TM) for transplantation research programme - Transition Therapeutics; Islet Neogenesis Therapy for transplantation research programme - Transition Therapeutics
Latest Information Update: 24 Aug 2010
At a glance
- Originator Transition Therapeutics
- Class Growth factors
- Mechanism of Action Somatotropin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 26 Oct 2004 Preclinical trials in Type-1 diabetes mellitus in Canada (unspecified route)